Presentation Type

Poster

Title of Abstract

Regulation of Interleukin-10 by HDACs on Mantle Cell Lymphoma

Abstract

Mantle Cell Lymphoma still remains one of the aggressive and incurable B cell malignancies. New approaches to treat MCL are being proposed, including epigenetic regulation as a way to alter gene expression, which could subsequently induce immune priming over immune tolerance. Histone deacetylases are key players in the regulation of a wide variety of genes and could have a central role in anergy. IL-10 is a primary cytokine in the inhibition of the immune response; its effect must be overcome in order to achieve a better immune response. We studied the expression of IL-10 in B cell lines as a model of Antigen Presenting Cells after treatment with the pan-inhibitor Trichostatin A and the HDAC 6 specific inhibitor Compound 7, in order to elucidate the role of HDACs in the regulation of IL-10, and thus the consequent implications in the inhibition of the immune response. We found that HDACs inhibitors abrogate the Lypopolysaccharide mediated up-regulation of IL-10 in B cells. Also HDAC6 inhibition considerably diminished IL-10 expression in B cells pointing to a positive correlation between HDAC 6 and IL-10. These preliminary findings point to HDAC6 as a primary player in the improvement of the immune response.

Categories

Biomedical Sciences

Research Type

Research Assistant

Mentor Information

Dr. Eva Sahakian

This document is currently not available here.

Share

COinS
 

Regulation of Interleukin-10 by HDACs on Mantle Cell Lymphoma

Mantle Cell Lymphoma still remains one of the aggressive and incurable B cell malignancies. New approaches to treat MCL are being proposed, including epigenetic regulation as a way to alter gene expression, which could subsequently induce immune priming over immune tolerance. Histone deacetylases are key players in the regulation of a wide variety of genes and could have a central role in anergy. IL-10 is a primary cytokine in the inhibition of the immune response; its effect must be overcome in order to achieve a better immune response. We studied the expression of IL-10 in B cell lines as a model of Antigen Presenting Cells after treatment with the pan-inhibitor Trichostatin A and the HDAC 6 specific inhibitor Compound 7, in order to elucidate the role of HDACs in the regulation of IL-10, and thus the consequent implications in the inhibition of the immune response. We found that HDACs inhibitors abrogate the Lypopolysaccharide mediated up-regulation of IL-10 in B cells. Also HDAC6 inhibition considerably diminished IL-10 expression in B cells pointing to a positive correlation between HDAC 6 and IL-10. These preliminary findings point to HDAC6 as a primary player in the improvement of the immune response.